IL-23p19 Antagonists vs. Ustekinumab for Treatment of Crohn&apos;s Disease: A Meta-analysis of Randomized Controlled Trials

Inflammatory Bowel Disease

Placebo rates in Crohn's disease randomized clinical trials: An individual patient data meta-analysis

Gastroenterology

Solitano V, Hogan M, Singh S, Danese S, Peyrin-Biroulet L, Zou G, Yuan Y, Sands BE, Feagan BG, Dulai PS, Narula N, Ma C, Jairath V

doi: 10.1053/j.gastro.2024.10.009

Inflammatory Bowel Disease

Re-evaluating Methods for Assessing Differences in Response in Ileal vs. Colonic Crohn's Disease: A Post-hoc Analysis of the FITZROY Trial

J Crohns Colitis

Ma C, Feagan BG, Wang Z, Zou G, Smith MI, Shackelton LM, Sands BE, Panaccione R, D'Haens GR, Vermeire S, Jairath V

doi: 10.1093/ecco-jcc/jjae113

Inflammatory Bowel Disease

Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Crohn's Disease and Ulcerative Colitis: 2-Year Results from Open-Label Extensions of Two Randomized Controlled Trials (LIBERTY)

J Crohns Colitis

Colombel JF, Sandborn WJ, Schreiber S, Danese S, Kłopocka M, Kierkuś J, Kulynych R, Gonciarz M, Sołtysiak A, Smoliński P, Srećković S, Valuyskikh E, Lahat A, Horyński M, Gasbarrini A, Osipenko M, Borzan V, Kowalski M, Saenko D, Sardinov R, Lee SJ, Kim S, Bae Y, Lee S, Lee S, Lee JH, Kim JM, Park G, Lee J, Lee J, Ryu JY, Sands BE, Hanauer SB

doi: 10.1093/ecco-jcc/jjaf060

Further Publications

Early tumour necrosis factor antagonist treatment prevents perianal fistula development in children with Crohn's disease: post hoc analysis of the RISK study

Gut

Adler J, Gadepalli S, Rahman M, Kim S

doi: 10.1136/gutjnl-2024-333280

Inflammatory Bowel Disease

Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial

Lancet Gastroenterol Hepatol

D'Haens G, Taxonera C, Lopez-Sanroman A, Nos P, Danese S, Armuzzi A, Roblin X, Peyrin-Biroulet L, West R, Mares WGN, Duijvestein M, Gecse KB, Feagan BG, Zou G, Hulshoff MS, Mookhoek A, Oldenburg L, Clasquin E, Bouhnik Y, Laharie D

doi: 10.1016/S2468-1253(24)00317-0

Inflammatory Bowel Disease

Effect of mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease on postoperative endoscopic recurrence (SPICY): an international, randomised controlled trial

Lancet Gastroenterol Hepatol

van der Does de Willebois EML, Bellato V, Duijvestein M, van der Bilt JDW, van Dongen K, Spinelli A, D'Haens GR, Mundt MW, Furfaro F, Danese S, Vignali A, Bemelman WA, Buskens CJ, SPICY collaborator group

doi: 10.1016/S2468-1253(24)00097-9

Inflammatory Bowel Disease

Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis

J Crohns Colitis

D'Haens G, Danese S, Panaccione R, Rubin DT, Peyrin-Biroulet L, Matsuoka K, Loftus EV Jr, Kobayashi T, Elsharkawi W, Miceli R, Ahmed S, Luo Y, Napoli A, Vaile J, Dornic Q, Patel A, Schreiber S

doi: 10.1093/ecco-jcc/jjaf080

Further Publications

Comparative Improvement in Health-Related Quality of Life with Advanced Therapies for Moderate-to-Severe Crohn's Disease: A Network Meta-Analysis

Am J Gastroenterol

Olivera PA, Parks ML, Zubiaurre I, Peyrin-Biroulet L, Lasa JS, Targownik LE

doi: 10.14309/ajg.0000000000003333

Further Publications

A Prospective Comparison of Ustekinumab and Anti-TNF Therapy in the Treatment of Crohn's-like Disease of the Pouch

Am J Gastroenterol

Barnes EL, Raffals L, Qazi T, Deepak P, Chang S, Beniwal-Patel P, Higgins PD, Cross RK, Barr JI, Anderson C, Long MD, Herfarth HH, Dubinsky M, Kappelman MD, Kayal M

doi: 10.14309/ajg.0000000000003608

Related content

Placebo rates in Crohn's disease randomized clinical trials: An individual patient data meta-analysis

Re-evaluating Methods for Assessing Differences in Response in Ileal vs. Colonic Crohn's Disease: A Post-hoc Analysis of the FITZROY Trial

Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Crohn's Disease and Ulcerative Colitis: 2-Year Results from Open-Label Extensions of Two Randomized Controlled Trials (LIBERTY)

Early tumour necrosis factor antagonist treatment prevents perianal fistula development in children with Crohn's disease: post hoc analysis of the RISK study

Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial

Effect of mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease on postoperative endoscopic recurrence (SPICY): an international, randomised controlled trial

Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis

Comparative Improvement in Health-Related Quality of Life with Advanced Therapies for Moderate-to-Severe Crohn's Disease: A Network Meta-Analysis

A Prospective Comparison of Ustekinumab and Anti-TNF Therapy in the Treatment of Crohn's-like Disease of the Pouch